Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on March 9, 2010. The report addresses a significant change in corporate governance involving the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Resignation: Mr. Eli Hurvitz resigned as Chairman of the Board and as a member of the Board of Directors effective March 9, 2010.
- Reason for Departure: Mr. Hurvitz resigned to focus on recovering from a recently diagnosed illness.
- Appointment: The Board of Directors unanimously appointed Mr. Zeev Bronfeld, a longstanding board member, to serve as Interim Chairman of the Board, effective immediately.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or specific risk factors beyond the immediate impact of the Chairman's resignation. The company issued a press release (Exhibit 99.1) to announce these events.
Key Facts for Investor Verification
- Confirm the health status and potential return timeline of former Chairman Eli Hurvitz.
- Verify the background and tenure of Interim Chairman Zeev Bronfeld.
- Monitor for any subsequent filings regarding the election of a permanent Chairman.
- Check for any undisclosed financial implications related to the leadership transition.